2025-524768-39-00RecruitingPhase 4
The pilot bioavailability study comparing the absorption of carbetocin (which is used as prevention of heavy bleeding after childbirth) in PABAL 100 μg/mL Solution for Injection when administered sublingually in the dose of 500 μg and intramuscularly in the dose of 100 μg.
Oxytone Bioscience B.V.1 site in 1 country4 target enrollmentStarted: February 9, 2026Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
- Sponsor
- Enrollment
- 4
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Yvone van Rijswick
Scientific
Oxytone Bioscience B.V.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Phase 1 Study Evaluating Relative Bioavailability of Sprinkled Ritlecitinib in Applesauce, Yoghurt, and Strawberry Jam and Evaluating the Effect of Food on the Bioavailability of Ritlecitinib Intact Blend-In Capsule in Healthy Adult Participants.Alopecia Areata, Rheumatoid Arthritis, Vitiligo, Ulcerative Colitis and Crohn's Disease2022-502872-22-00Pfizer Inc.12
Recruiting
Phase 1
A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy SubjectsCardiomyopathyNCT07272330Shandong Suncadia Medicine Co., Ltd.38
Completed
Phase 1
Randomized, crossover, comparative bioavailability study of two Paracetamol-Ibuprofen 25-20 mg/ml oral suspension, administered in single dose to healthy subjects under fasting conditions.Healthy volunteers2024-519661-22-00Farmalider S.A.24
Completed
Phase 1
A study in healthy people to compare 2 different formulations of nerandomilast tablets when taken with or without foodHealthy volunteer trial2024-511245-18-00Boehringer Ingelheim International GmbH15
Completed
Phase 1
Evaluation of the bioavailability of two transdermal gel preparations containing 0.1% w/w estradiol under fasting conditions: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA® 0.1%, gel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy postmenopausal womenNo therapeutic indication in the current trial with healthy volunteers.2024-517969-16-00CCDRD Cooperative Clinical Drug Research and Development AG, Ioulia And Irene Tseti Pharmaceutical Laboratories S.A.18